KR20220011652A - 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법 - Google Patents

브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법 Download PDF

Info

Publication number
KR20220011652A
KR20220011652A KR1020217039591A KR20217039591A KR20220011652A KR 20220011652 A KR20220011652 A KR 20220011652A KR 1020217039591 A KR1020217039591 A KR 1020217039591A KR 20217039591 A KR20217039591 A KR 20217039591A KR 20220011652 A KR20220011652 A KR 20220011652A
Authority
KR
South Korea
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217039591A
Other languages
English (en)
Korean (ko)
Inventor
수비크 바타차르야
브루노 비에트
마치에이 카반스키
브루노 첸니
스테팡 드 뷔크
마르틴 카울
아르빈드 키니카르
안드리야나 라디보예비치
알레산드라 비탈리티 가라미
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20220011652A publication Critical patent/KR20220011652A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217039591A 2019-05-23 2020-05-20 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법 Pending KR20220011652A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851994P 2019-05-23 2019-05-23
US62/851,994 2019-05-23
PCT/IB2020/054754 WO2020234781A1 (en) 2019-05-23 2020-05-20 Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
KR20220011652A true KR20220011652A (ko) 2022-01-28

Family

ID=70918750

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217039591A Pending KR20220011652A (ko) 2019-05-23 2020-05-20 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법

Country Status (23)

Country Link
US (2) US12383556B2 (enExample)
EP (2) EP3972603B1 (enExample)
JP (2) JP7765970B2 (enExample)
KR (1) KR20220011652A (enExample)
CN (1) CN113811301A (enExample)
AU (2) AU2020278236C1 (enExample)
BR (1) BR112021023110A2 (enExample)
CA (1) CA3137271A1 (enExample)
CL (1) CL2021003034A1 (enExample)
DK (1) DK3972603T3 (enExample)
ES (1) ES3004516T3 (enExample)
FI (1) FI3972603T3 (enExample)
HR (1) HRP20241584T1 (enExample)
HU (1) HUE069020T2 (enExample)
IL (1) IL287745B2 (enExample)
LT (1) LT3972603T (enExample)
MX (1) MX2021014161A (enExample)
PL (1) PL3972603T3 (enExample)
PT (1) PT3972603T (enExample)
RS (1) RS66195B1 (enExample)
SI (1) SI3972603T1 (enExample)
TW (1) TWI857060B (enExample)
WO (1) WO2020234781A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240148257A (ko) 2023-04-03 2024-10-11 주식회사 사이알바이오 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12383556B2 (en) 2019-05-23 2025-08-12 Novartis Ag Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor
EP4284344A1 (en) * 2021-01-26 2023-12-06 Novartis AG Pharmaceutical composition
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
CA3239276A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213100A (pt) 2001-10-05 2004-11-30 Combinatorx Inc Combinações para o tratamento de distúrbios imuniinflamatórios
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
HRP20211845T1 (hr) 2015-12-16 2022-03-04 Boehringer Ingelheim International Gmbh Derivati bipirazolila korisni za liječenje autoimunih bolesti
US10570118B2 (en) * 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
US10874741B2 (en) 2017-08-28 2020-12-29 Spectrix Therapeutics, LLC Compound to treat Sjogren's syndrome
EP3704158A1 (en) 2017-11-03 2020-09-09 Novartis AG Anti-cd40 antibodies for use in treatment of sjögren's syndrome
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
US12383556B2 (en) 2019-05-23 2025-08-12 Novartis Ag Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240148257A (ko) 2023-04-03 2024-10-11 주식회사 사이알바이오 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
PL3972603T3 (pl) 2025-02-03
BR112021023110A2 (pt) 2022-04-12
IL287745A (en) 2021-12-01
DK3972603T3 (da) 2024-12-02
EP4442321A2 (en) 2024-10-09
SI3972603T1 (sl) 2025-02-28
MX2021014161A (es) 2022-01-04
AU2020278236B2 (en) 2025-08-07
RS66195B1 (sr) 2024-12-31
EP4442321A3 (en) 2025-01-01
JP2022533968A (ja) 2022-07-27
PT3972603T (pt) 2024-11-26
FI3972603T3 (fi) 2024-12-04
US20220175772A1 (en) 2022-06-09
JP7765970B2 (ja) 2025-11-07
TW202110451A (zh) 2021-03-16
AU2020278236C1 (en) 2026-02-26
CL2021003034A1 (es) 2022-09-09
WO2020234781A1 (en) 2020-11-26
TWI857060B (zh) 2024-10-01
EP3972603B1 (en) 2024-09-04
EP3972603A1 (en) 2022-03-30
HRP20241584T1 (hr) 2025-01-31
HUE069020T2 (hu) 2025-02-28
US12383556B2 (en) 2025-08-12
JP2025165957A (ja) 2025-11-05
CN113811301A (zh) 2021-12-17
US20250339428A1 (en) 2025-11-06
AU2020278236A1 (en) 2022-01-06
IL287745B2 (en) 2026-02-01
IL287745B1 (en) 2025-10-01
CA3137271A1 (en) 2020-11-26
ES3004516T3 (en) 2025-03-12
AU2020278236A8 (en) 2022-04-28
LT3972603T (lt) 2024-12-10
AU2025263830A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
JP7765970B2 (ja) ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法
JP7568651B2 (ja) ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
Higgins et al. Studies to examine potential tolerability differences between the 5-HT2C receptor selective agonists lorcaserin and CP-809101
US20250090538A1 (en) Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease
RU2824354C2 (ru) Способы лечения синдрома шегрена с применением ингибитора тирозинкиназы брутона
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
HK40110203A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
HK40061327B (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
HK40061327A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
RU2847617C2 (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
RU2818678C2 (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
HK40126655A (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
HK40061328B (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
HK40061328A (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701